Novo Nordisk Securities Litigation Settlement
This settlement is closed to new claims. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Novo Nordisk and three individual defendants allegedly violated federal securities laws by making false and misleading statements about the company's business and financial results. The defendants deny all allegations and maintain valid defenses to the claims. The parties reached a settlement for $100 million.
Do you qualify?
Anyone who purchased American Depositary Receipts (ADRs) of Novo Nordisk A/S between February 3, 2015 and February 2, 2017, inclusive, and who were damaged thereby. Excluded are Novo Nordisk itself, directors and officers, subsidiaries, affiliates, and anyone who requested exclusion.
How to file
Claims administration is now complete as of June 2023. Net settlement funds have been distributed in June 2024 and July 28, 2025, with subsequent distributions to occur on a rolling basis. Contact the Claims Administrator at 1-833-674-0167 or info@NovoNordiskSecuritiesLitigation.com for more information.
Common questions
- How much does the Novo Nordisk Securities Litigation Settlement pay?
- The total settlement fund is $100M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- Is the Novo Nordisk Securities Litigation Settlement notice real, or a scam?
- JND Legal Administration is the settlement administrator for this case. Claims are filed at novonordisksecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the Novo Nordisk Securities Litigation Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for July 13, 2022; no payments can be issued before a settlement receives final approval.
In the news
- Novo Nordisk Sues Hims & Hers Over Ozempic Copycats as the Weight-Loss Drug Wars EscalateGizmodo.com · February 9, 2026
- Hims & Hers Health (NYSE:HIMS) Faces Class Action After Partnership Termination With Novo NordiskYahoo Entertainment · June 26, 2025
- Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slumpQuartz India · April 2, 2025
- Novo Nordisk agrees to cap insulin prices in Minnesota settlementQuartz India · January 27, 2025
Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Revance Securities Settlement
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Not yet determinable; depends on number of valid claims submitted
Biogen Securities Litigation Settlement
Biogen Inc. investors have settled a securities litigation case for $18.9 million in cash. The settlement resolves claims related to purchases of Biogen common stock during the specified class period.
NJ Bureau of Securities Settlement with Credit Suisse
Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.
Stitch Fix Securities Litigation Settlement
Stitch Fix, Inc. is settling a securities class action lawsuit without admitting wrongdoing. The Lead Plaintiffs alleged that Stitch Fix issued misleading statements about its business, and shareholders who purchased the stock during the class period suffered damages as a result.